Organism: Homo sapiens
Gene: 39516_at
Selected probe(set): 204839_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39516_at (204839_at) across 6674 perturbations tested by GENEVESTIGATOR:

Relative Expression (log2-ratio):3.4486284
Number of Samples:4 / 4

Experimental	B-CLL study 11 (rolipram)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control	rolipram study 4 (normal B-cell; 20uM)
	MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

Relative Expression (log2-ratio):-3.195261
Number of Samples:5 / 4

Experimental	house dust mite study 2 (allergic)
	Primary nasal epithelial cells from subjects with monotypical allergy to house dust mite (HDM) were exposed to house dust mite extract (2µg/ml) for 24 hours. Subjects (19-55 years old) were selected based on skin prick test for HDM and other common allergens. The subjects had refrained from using any medication for their allergy in the 4 weeks before the samples collection. Nasal biopsies for isolation of primary cells were taken from the lower edge of the inferior turbinate, and 2 cm from the anterior end.
Control	house dust mite study 2 (non-allergic)
	Primary nasal epithelial cells from healthy subjects with no allergies were exposed to house dust mite (HDM) extract (2µg/ml) for 24 hours. Subjects (21-32 years old) were selected based on skin prick test for HDM and other common allergens. Nasal biopsies for isolation of primary cells were taken from the lower edge of the inferior turbinate, and 2 cm from the anterior end.

Relative Expression (log2-ratio):3.0818958
Number of Samples:4 / 4

Experimental	B-CLL study 11 (DMSO)
	Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control	vehicle (DMSO) treated normal B-cell sample
	MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

Relative Expression (log2-ratio):-2.717537
Number of Samples:6 / 12

Experimental	IL-4; GM-CSF study 1 (early)
	Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 6 hours.
Control	untreated monocyte sample
	Freshly isolated human monocytes from healthy donors.

Relative Expression (log2-ratio):-2.6944485
Number of Samples:4 / 6

Experimental	F. tularensis study 1 (tularensis Schu S4)
	Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours.
Control	uninfected peripheral blood monocyte sample
	Peripheral blood monocytes uninfected.

Relative Expression (log2-ratio):-2.5675354
Number of Samples:4 / 6

Experimental	F. tularensis study 1 (novicida)
	Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control	uninfected peripheral blood monocyte sample
	Peripheral blood monocytes uninfected.

Relative Expression (log2-ratio):-2.397252
Number of Samples:3 / 3

Experimental	kidney transplantation study 16 (2 week)
	CD56+ natural killer cell samples derived from kidney transplant patients 2 weeks post-transplantation. Samples were collected 2 week after transplantation and administration of immunosuppressive therapy (day 1-4: methylprednisolone (60 mg); 3 doses: rabbit polyclonal anti-thymocyte globulin (ThymoglobulinH; 6 mg/kg); mycophenolate mofetil (CellCeptH); and tacrolimus (PrografH).
Control	normal natural killer cell (CD56+) sample
	CD56+ natural killer cell samples derived from healthy control subjects.

Relative Expression (log2-ratio):-2.2451038
Number of Samples:4 / 3

Experimental	tumor supernatant activation study 3
	Memory (CD45RA-) CD4+ T cells isolated from peripheral blood of female healthy donors were incubated for 24 hours in 1:1 mix of tumor supernatant from primary invasive breast ductal carcinoma and X-VIVO 20 medium supplemented with antiCD3/CD28 beads, before harvest for RNA isolation. The tumor supernatant was prepared as followed: fresh surgical specimen was dissociated in X-VIVO 20 medium by GentleMACS dissociator and the resulting suspension was clarified by centrifugation for 15min at 13'000 g. ATC code:---
Control	memory T-cell activation study 1
	Memory (CD45RA-) CD4+ T-cells isolated from peripheral blood of healthy female donors were activated with anti-CD3/CD28 beads for 24hrs.

Relative Expression (log2-ratio):2.0653229
Number of Samples:2 / 4

Experimental	glioma study 17 ( small cell glioblastoma; unsorted)
	Brain cells isolated from high grade small cell glioblastoma (grade IV). Tumor tissue was dissociated using enzymatic treatment and all cells were used for RNA isolation. Patients were 56 ± 3 years old males.
Control	non-tumor cortical tissue
	Cortical tissue obtained from patients with epilepsy, but without any manifested brain cancer. The tissue was dissociated using enzymatic treatment, but all brain cell types were used for analyses.

Relative Expression (log2-ratio):2.0337362
Number of Samples:2 / 3

Experimental	glioma study 16 (LN-18)
	Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2.
Control	normal astrocyte sample
	Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.